Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 75
Filter
Add more filters

Publication year range
1.
J Tradit Chin Med ; 44(2): 277-288, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38504534

ABSTRACT

OBJECTIVE: To analyze the effect and molecular mechanism of Gehua Jiejiu Dizhi decoction (, GJDD) on alcoholic fatty live disease (AFLD) by using proteomic methods. METHODS: The male C57BL/6J mouse were randomly divided into four groups: control group, model group, GJDD group and resveratrol group. After the AFLD model was successfully prepared by intragastric administration of alcohol once on the basis of the Lieber-DeCarli classical method, the GJDD group and resveratrol group were intragastrically administered with GJDD (4900 mg/kg) and resveratrol (400 mg/kg) respectively, once a day for 9 d. The fat deposition of liver tissue was observed and evaluated by oil red O (ORO) staining. 4DLabel-free quantitative proteome method was used to determine and quantify the protein expression in liver tissue of each experimental group. The differentially expressed proteins were screened according to protein expression differential multiples, and then analyzed by Gene ontology classification and Kyoto Encyclopedia of Genes and Genomes pathway enrichment. Finally, expression validation of the differentially co-expressed proteins from control group, model group and GJDD group were verified by targeted proteomics quantification techniques. RESULTS: In semiquantitative analyses of ORO, all kinds of steatosis (ToS, MaS, and MiS) were evaluated higher in AFLD mice compared to those in GJDD or resveratrol-treated mice. 4DLabel-free proteomics analysis results showed that a total of 4513 proteins were identified, of which 3763 proteins were quantified and 946 differentially expressed proteins were screened. Compared with the control group, 145 proteins were up-regulated and 148 proteins were down-regulated in the liver tissue of model group. In addition, compared with the model group, 92 proteins were up-regulated and 135 proteins were down-regulated in the liver tissue of the GJDD group. 15 differentially co-expressed proteins were found between every two groups (model group vs control group, GJDD group vs model group and GJDD group vs control group), which were involved in many biological processes. Among them, 11 differentially co-expressed key proteins (Aox3, H1-5, Fabp5, Ces3a, Nudt7, Serpinb1a, Fkbp11, Rpl22l1, Keg1, Acss2 and Slco1a1) were further identified by targeted proteomic quantitative technology and their expression patterns were consistent with the results of 4D label-free proteomic analysis. CONCLUSIONS: Our study provided proteomics-based evidence that GJDD alleviated AFLD by modulating liver protein expression, likely through the modulation of lipid metabolism, bile acid metabolism and with exertion of antioxidant stress.


Subject(s)
Fatty Liver, Alcoholic , Serpins , Mice , Male , Animals , Fatty Liver, Alcoholic/drug therapy , Fatty Liver, Alcoholic/genetics , Fatty Liver, Alcoholic/metabolism , Antioxidants/metabolism , Proteomics/methods , Resveratrol/metabolism , Physical Exertion , Mice, Inbred C57BL , Liver/metabolism , Lipid Metabolism , Bile Acids and Salts/metabolism , Lipids , Serpins/metabolism , Aldehyde Oxidoreductases/metabolism
2.
J Ethnopharmacol ; 307: 116227, 2023 May 10.
Article in English | MEDLINE | ID: mdl-36739928

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Verbenalin is a major compound in Verbena officinalis L. Verbena officinalis L was first recorded in the 'Supplementary Records of Famous Physicians.' Verbenalin (VE) is its active constituent and has been found to have many biological effects, including anti-obesity, anti-inflammatory, and antioxidant activities, removing jaundice, and treating malaria. It could treat lump accumulation, dysmenorrhea, throat obstruction, edema, jaundice, and malaria. Palmitic acid (PA), oleic acid (OA), ethanol, and acetaminophen liver injuries have been proven to benefit from verbenalin. AIM OF THE STUDY: To study the effects of verbenalin on the prevention of alcoholic steatohepatitis (ASH) through the regulation of oxidative stress and mitochondrial dysfunction by regulating MDMX (Murine double minute X)/PPARα (Peroxisome proliferator-activated receptor alpha)-mediated ferroptosis. MATERIAL AND METHODS: C57BL/6 mice treated with alcohol followed by the Gao-Binge protocol were administered verbenalin by gavage simultaneously. The mitochondrial mass and morphology were visualized using TEM. AML-12 cells were stimulated with ethanol to mimic ASH in vitro. Western blotting, co-immunoprecipitation, and kit determination were simultaneously performed. The target protein of verbenalin was identified by molecular docking, and cellular thermal shift assay (CETSA) further confirmed its interactions. RESULTS: Verbenalin alleviates oxidative stress and ferroptosis in alcohol-associated steatohepatitis. To elucidate the molecular mechanism by which verbenalin inhibits abnormal mitochondrial dysfunction, molecular docking was performed, and MDMX was identified as the target protein of verbenalin. CETSA assays revealed a specific interaction between MDMX and verbenalin. Co-immunoprecipitation demonstrated that PPARα played a critical role in promoting the ability of MDMX to affect ferroptosis. Verbenalin regulates MDMX/PPARα-mediated ferroptosis in AML-12 cells. CONCLUSION: Verbenalin regulates ferroptosis and highlights the therapeutic potential of verbenalin and ferroptosis inhibition in reducing alcoholic steatohepatitis.


Subject(s)
Fatty Liver, Alcoholic , Ferroptosis , Leukemia, Myeloid, Acute , Non-alcoholic Fatty Liver Disease , Animals , Female , Mice , Ethanol/pharmacology , Fatty Liver, Alcoholic/metabolism , Leukemia, Myeloid, Acute/metabolism , Liver , Mice, Inbred C57BL , Mitochondria/metabolism , Molecular Docking Simulation , Non-alcoholic Fatty Liver Disease/metabolism , PPAR alpha/metabolism , Proteins/metabolism
3.
Food Funct ; 14(3): 1573-1583, 2023 Feb 06.
Article in English | MEDLINE | ID: mdl-36655918

ABSTRACT

Dietary oil composition determines the pathological processes of alcoholic fatty liver disease (AFLD). Oil rich in saturated fatty acids protects, whereas oil rich in polyunsaturated fatty acids aggravates the alcohol-induced liver injury. However, limited studies have been conducted to address how monounsaturated fatty acids (MUFAs) enriched oil controls the pathological development of AFLD. Therefore, this study was designed to evaluate the effect of MUFA-enriched extra virgin olive oil (OO) on AFLD. Twenty C57BL/6J mice were randomly allocated into four groups and fed modified Lieber-DeCarli liquid diets containing isocaloric maltose dextrin a non-alcohol or alcohol with corn oil and OO for four weeks. Dietary OO significantly exacerbated alcohol-induced liver dysfunction, evidenced by histological examinations and disturbed biochemical parameters. Dietary OO with alcohol decreased hormone-sensitive lipase (HSL), phosphorylated 5'-AMP-activated protein kinase (p-AMPK), and carnitine palmitoyltransferase-Iα (CPT1α) expression, and increased sterol regulatory element-binding protein-1c (SREBP-1c), diacylglycerol acyltransferase-2 (DGAT2), and very low-density lipoprotein receptor (VLDLR) expression in the liver. It also promoted the expression of hepatic interleukin-6 (IL-6) and hepatic tumour necrosis factor-alpha (TNF-α) at the transcriptional level. Additionally, adipose tissue lipolysis partially had an etiologic effect on alcohol-induced hepatic steatosis under OO pretreatment. In conclusion, MUFA-enriched OO exacerbated liver dysfunction in vivo. OO should be cautiously considered as a unique dietary oil source for individuals with AFLD.


Subject(s)
Fatty Liver, Alcoholic , Mice , Animals , Olive Oil/pharmacology , Fatty Liver, Alcoholic/etiology , Fatty Liver, Alcoholic/metabolism , Fatty Acids, Monounsaturated/metabolism , Mice, Inbred C57BL , Liver/metabolism , Ethanol/metabolism , Fatty Acids/metabolism , Corn Oil/metabolism
4.
J Med Food ; 25(12): 1102-1111, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36516056

ABSTRACT

Alcoholic liver disease (ALD) is a major chronic liver disease. Chronic alcohol consumption induces dysbiosis, disruption of gut barrier function, oxidative stress, inflammation, and changes in lipid metabolism, thereby leading to ALD. In this study, we investigated whether the commercial Morinda citrifolia extract Nonitri can ameliorate ALD symptoms through the gut-liver axis. We used mice chronically administered EtOH and found a marked increase in serum endotoxin levels and biomarkers of liver pathology. Moreover, the EtOH-treated group showed significantly altered gut microbial composition particularly that of Alistipes, Bacteroides, and Muribaculum and disrupted gut barrier function. However, Nonitri improved serum parameters, restored the microbial proportions, and regulated levels of zonula occludens1, occludin, and claudin1. Furthermore, Nonitri suppressed inflammation by inhibiting endotoxin-triggered toll-like receptor 4-signaling pathway and fat deposition by reducing lipogenesis through activating AMP-activated protein kinase in the liver. Furthermore, Pearson's correlation analysis showed that gut microbiota and ALD-related markers were correlated, and Nonitri regulated these bacteria. Taken together, our results indicate that the hepatoprotective effect of Nonitri reduces endotoxin levels by improving gut health, and inhibits fat deposition by regulating lipid metabolism.


Subject(s)
Fatty Liver, Alcoholic , Liver Diseases, Alcoholic , Morinda , Mice , Animals , Fatty Liver, Alcoholic/drug therapy , Fatty Liver, Alcoholic/metabolism , Dysbiosis/microbiology , Liver Diseases, Alcoholic/drug therapy , Liver Diseases, Alcoholic/prevention & control , Liver/metabolism , Ethanol/metabolism , Endotoxins , Inflammation/metabolism , Mice, Inbred C57BL
5.
J Ethnopharmacol ; 295: 115407, 2022 Sep 15.
Article in English | MEDLINE | ID: mdl-35640740

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Our previous studies found that the ethanol extract of Gynura procumbens (EEGS) reduced hepatic steatosis in alcoholic fatty liver disease (AFLD). AIM OF THE STUDY: To explore the active ingredients from EEGS and their relevant mechanism of action in alleviating alcoholic liver injuries. AIM OF THE STUDY: To explore the active ingredients from EEGS and their intestinal absorption characteristics as an approach for understanding mechanism of action in alleviating alcoholic liver injuries. MATERIALS AND METHODS: Monitored by high-performance liquid chromatography (HPLC) and thin-layer chromatography (TLC), chemical constituents from the prepared EEGS were isolated by means of solvent extraction, repeated column chromatography, preparative HPLC and other methods, and their structures were identified based on spectroscopic methods. The in vivo intestinal absorption rate of chlorogenic acid (CA), the active component of the EEGS, both in a single form and in the EEGS were monitored by the single-pass intestinal perfusion (SPIP) method in rats. The protective effect of EEGS and its active components on alcoholic liver injuries was evaluated in the alcoholic liver injury model of C57BL/6J male mice induced by Lieber-DeCarli alcohol liquid feed. RESULTS: Three noncaffeoyl quinic acid components were isolated and identified from the EEGS, namely, 3-trans-p-coumaroyl quinic acid (0.9%), 3-cis-p-coumaroyl quinic acid (2.7%), and trans-p-coumaric acid (0.6%). In vivo intestinal absorption of CA decreased with the increase of pH value of perfusion solution in the range of 5.5-7.8. The maximum absorption percentage of CA alone was 6.7 ± 2.4%, while the maximum absorption percentage of CA in the EEGS was 16.0 ± 2.2%, which was 2.4 times higher than that of CA alone. The results of animal experiments showed that the degree of fatty liver of mice treated with EEGS was significantly lower than that of the CA, trans-p-coumaric acid, and the combination group of CA and trans-p-coumaric acid alone. CONCLUSION: The above results indicated that trans-p-coumaric acid isolated from the dried stems of Gynura procumbens assisted CA being absorbed into the body and worked together with CA to improve the function of liver lipid metabolism, reduce hepatic lipid accumulation in a mouse model of AFLD and effectively counteract alcohol-induced fatty liver disease.


Subject(s)
Asteraceae , Fatty Liver, Alcoholic , Fatty Liver , Animals , Asteraceae/chemistry , Chlorogenic Acid/therapeutic use , Coumaric Acids , Ethanol/chemistry , Fatty Liver/drug therapy , Fatty Liver, Alcoholic/metabolism , Intestinal Absorption , Liver , Male , Mice , Mice, Inbred C57BL , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Quinic Acid/pharmacology , Rats
6.
J Med Food ; 25(4): 456-463, 2022 Apr.
Article in English | MEDLINE | ID: mdl-35438556

ABSTRACT

We examined the efficacy of fermented Curcuma longa L. (FT) on the development of alcoholic fatty liver in mice and investigated the underlying mechanism. The protective potential of FT against ethanol-induced fatty liver was determined using C57BL/6 male mice allocated into four groups (8 mice/group). Control groups received either distilled water or 5 g/kg body weight (b.w.) per day ethanol for 8 days. Treatment groups were administered either 300 mg/kg b.w. per day of milk thistle or FT before receiving ethanol. FT contained a higher amount of caffeic acid and tetrahydrocurcumin than C. longa. FT pretreatment significantly suppressed the elevated hepatic lipid droplets associated with ethanol ingestion. In comparison with ethanol-treated control, FT pretreated mice showed inhibited cytochrome P4502E1 (CYP2E1), sterol regulatory element-binding protein-1 (SREBP-1c), and acetyl-CoA carboxylase production but elevated AMP-activated protein kinase, peroxisome proliferator-activated receptor-alpha (PPAR-α), and carnitine palmitoyltransferase 1 (CPT-1) levels. Taken together, FT is a promising hepatoprotectant for preventing of alcoholic fatty liver through modulating fatty acid synthesis and oxidation.


Subject(s)
Fatty Liver, Alcoholic , Non-alcoholic Fatty Liver Disease , Animals , Curcuma , Cytochrome P-450 CYP2E1/genetics , Cytochrome P-450 CYP2E1/metabolism , Ethanol/metabolism , Fatty Liver, Alcoholic/drug therapy , Fatty Liver, Alcoholic/metabolism , Fatty Liver, Alcoholic/prevention & control , Female , Liver/metabolism , Male , Mice , Mice, Inbred C57BL , Non-alcoholic Fatty Liver Disease/metabolism , PPAR alpha/genetics , PPAR alpha/metabolism , Sterol Regulatory Element Binding Protein 1/genetics , Sterol Regulatory Element Binding Protein 1/metabolism
7.
Arch Biochem Biophys ; 722: 109236, 2022 06 15.
Article in English | MEDLINE | ID: mdl-35429444

ABSTRACT

Baicalin is a flavonoid compound abundant in multiple edible and medicinal plants such as Scutellaria baicalensis Georgi. In this study, we provide evidence to support the fact that baicalin ameliorates alcohol-induced hepatic steatosis via regulating SREBP1c elicited PNPLA3 competitive binding to ATGL. Results showed that baicalin significantly attenuated the development of metabolic disorders and hepatic steatosis in alcohol-induced rats after four weeks of treatment. It was evident that baicalin treatment significantly normalized the serous contents of hepatic triglyceride (TG), alanine aminotransferase (ALT), and aspartate aminotransferase (AST), and attenuated the increase of hepatic vacuolization and Oil Red O staining area caused by alcohol. Meanwhile, baicalin relieves alcohol-induced hepatic fibrosis by masson staining and RT-qPCR analysis. Mechanistically, alcohol aggravated the nuclear expression of SREBP1c, which contributed to the high expression of PNPLA3 and FASN, thereby enhancing the binding of PNPLA3 to ABHD5, and indirectly impairing the binding ability between ATGL and ABHD5, ultimately causing a decline in the hydrolysis capacity in liver lipid droplets. As expected, these alcohol-induced pathobolism were reversed by baicalin treatment both in vivo and in vitro. In conclusion, this study has demonstrated that baicalin can protect against alcohol-induced hepatic lipid accumulation by activating hepatic lipolysis via suppressing SREBP1c elicited PNPLA3 competitive binding to ATGL. Baicalin is a promising natural product for preventing alcohol-induced hepatic steatosis.


Subject(s)
Fatty Liver, Alcoholic , Animals , Binding, Competitive , Ethanol/metabolism , Fatty Liver, Alcoholic/drug therapy , Fatty Liver, Alcoholic/metabolism , Flavonoids/metabolism , Flavonoids/pharmacology , Flavonoids/therapeutic use , Liver/metabolism , Rats , Sterol Regulatory Element Binding Protein 1/genetics
8.
J Ethnopharmacol ; 292: 115225, 2022 Jun 28.
Article in English | MEDLINE | ID: mdl-35341932

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: The therapeutic properties of Hippophae rhamnoides L. were already known in ancient Greece as well as in Tibetan and Mongolian medicine. Modern studies have indicated that Hippophae rhamnoides L. fermentation liquid protected against alcoholic fatty liver disease (AFLD). However, the underlying mechanism of Hippophae rhamnoides L. flavonoids extract (HLF) treating AFLD remains elusive. AIM OF THE STUDY: This study aimed to investigate the hepatoprotective effect of HLF in mice with AFLD and the interaction between AFLD and gut microbiota. MATERIALS AND METHODS: Chemical constituents of HLF were analyzed by Liquid Chromatography-Ion Trap-ESI-Mass Spectrometry. The Hepatoprotective effect of HLF was evaluated in mice with AFLD induced by alcohol (six groups, n = 10) daily at doses of 0.1, 0.2, and 0.4 g/kg for 30 consecutive days. At the end of experiment, mice were sacrificed and the liver, serum and feces were harvested for analysis. The liver histological changes were observed by H&E staining and oil red O staining. Moreover, the alterations of fecal microflora were detected by 16S rRNA gene sequencing. The inflammatory related genes were determined by qRT-PCR and western blotting respectively. RESULTS: The results showed that the oral administration of HLF remarkably alleviated hepatic lipid accumulation by decreasing the levels of ALT, AST, TG and TC. The levels of TNF-α, TGF-ß, and IL-6 were also reduced after treatment with HLF. Meanwhile, the protein and mRNA expression of NF-kB p65, MAPK p38 and TAK-1 in the liver of mice with AFLD were all reduced by HLF compared with model group. Furthermore, the 16S rRNA gene sequencing analysis demonstrated that HLF treatment can help restore the imbalance of intestinal microbial ecosystem and reverse the changes in Fimicutes/Bacterodietes, Clostridiales, Lachnospiraceae, S24-7, and Prevotella in mice with AFLD. CONCLUSION: HLF can effectively ameliorate liver injury in mice with AFLD, and regulate the composition of gut microbiota. Its regulatory mechanism may be related to TAK1/p38MAPK/p65NF-κB pathway. This study may provide novel insights into the mechanism of HLF on AFLD and a basis for promising clinical usage.


Subject(s)
Fatty Liver, Alcoholic , Gastrointestinal Microbiome , Hippophae , Animals , Ecosystem , Fatty Liver, Alcoholic/drug therapy , Fatty Liver, Alcoholic/metabolism , Flavonoids/metabolism , Flavonoids/pharmacology , Flavonoids/therapeutic use , Hippophae/chemistry , Liver , Mice , Plant Extracts/chemistry , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , RNA, Ribosomal, 16S/genetics , p38 Mitogen-Activated Protein Kinases/metabolism
9.
Molecules ; 27(3)2022 Jan 18.
Article in English | MEDLINE | ID: mdl-35163881

ABSTRACT

Ampelopsis grossedentata (AG) is an ancient medicinal plant that is mainly distributed and used in southwest China. It exerts therapeutic effects, such as antioxidant, anti-diabetic, and anti-inflammatory activities, reductions in blood pressure and cholesterol and hepatoprotective effects. Researchers in China recently reported the anti-obesity effects of AG extract in diet-induced obese mice and rats. To verify these findings, we herein investigated the effects of AG extract and its principal compound, ampelopsin, in high-fat diet (HFD)- and alcohol diet-fed mice, olive oil-loaded mice, and differentiated 3T3-L1 cells. The results obtained showed that AG extract and ampelopsin significantly suppressed increases in the weights of body, livers and abdominal fat and also up-regulated the expression of carnitine palmitoyltransferase 1A in HFD-fed mice. In olive oil-loaded mice, AG extract and ampelopsin significantly attenuated increases in serum triglyceride (TG) levels. In differentiated 3T3-L1 cells, AG extract and ampelopsin promoted TG decomposition, which appeared to be attributed to the expression of hormone-sensitive lipase. In alcohol diet-fed mice, AG extract and ampelopsin reduced serum levels of ethanol, glutamic oxaloacetic transaminase (GOT), and glutamic pyruvic transaminase (GPT) and liver TG. An examination of metabolic enzyme expression patterns revealed that AG extract and ampelopsin mainly enhanced the expression of aldehyde dehydrogenase and suppressed that of cytochrome P450, family 2, subfamily e1. In conclusion, AG extract and ampelopsin suppressed diet-induced intestinal fat accumulation and reduced the risk of fatty liver associated with HFD and alcohol consumption.


Subject(s)
Anti-Obesity Agents/pharmacology , Diet, High-Fat , Fatty Liver, Alcoholic/drug therapy , Flavonoids/pharmacology , Non-alcoholic Fatty Liver Disease/drug therapy , Plant Extracts/pharmacology , Tea/chemistry , 3T3-L1 Cells , Adiposity , Animals , Antioxidants/pharmacology , Fatty Liver, Alcoholic/etiology , Fatty Liver, Alcoholic/metabolism , Fatty Liver, Alcoholic/pathology , Lipid Metabolism , Lipogenesis , Male , Mice , Mice, Inbred C57BL , Mice, Inbred ICR , Mice, Obese , Non-alcoholic Fatty Liver Disease/etiology , Non-alcoholic Fatty Liver Disease/metabolism , Non-alcoholic Fatty Liver Disease/pathology , Obesity/drug therapy , Obesity/etiology , Obesity/metabolism , Obesity/pathology , Phytotherapy , Rats , Rats, Sprague-Dawley
10.
Nutrients ; 13(12)2021 Dec 13.
Article in English | MEDLINE | ID: mdl-34959999

ABSTRACT

In this study, we investigated the pharmacological effect of a water extract of Raphani Semen (RSWE) on alcoholic fatty liver disease (AFLD) using ethanol-induced AFLD mice (the NIAAA model) and palmitic acid (PA)-induced steatosis HepG2 cells. An RSWE supplement improved serum and hepatic triglyceride (TG) levels of AFLD mice, as well as their liver histological structure. To explore the molecular action of RSWE in the improvement of AFLD, we investigated the effect of RSWE on four major pathways for lipid homeostasis in the liver: free fatty acid transport, lipogenesis, lipolysis, and ß-oxidation. Importantly, RSWE decreased the mRNA expression of de novo lipogenesis-related genes, such as Srebf1, Cebpa, Pparg, and Lpin1, as well as the protein levels of these factors, in the liver of AFLD mice. That these actions of RSWE affect lipogenesis was confirmed using PA-induced steatosis HepG2 cells. Overall, our findings suggest that RSWE has the potential for improvement of AFLD by inhibiting de novo lipogenesis.


Subject(s)
Fatty Liver, Alcoholic/drug therapy , Lipogenesis/drug effects , Plant Extracts/pharmacology , Raphanus/chemistry , Seeds/chemistry , Animals , Ethanol/adverse effects , Fatty Acids, Nonesterified/metabolism , Fatty Liver, Alcoholic/metabolism , Hep G2 Cells , Humans , Lipid Metabolism/drug effects , Lipolysis/drug effects , Liver/metabolism , Male , Mice , Mice, Inbred C57BL , Oxidation-Reduction/drug effects , Palmitic Acid/adverse effects , Phosphatidate Phosphatase/metabolism , Sterol Regulatory Element Binding Protein 1/metabolism , Triglycerides/blood
11.
Molecules ; 26(22)2021 Nov 18.
Article in English | MEDLINE | ID: mdl-34834064

ABSTRACT

Alcohol is metabolized in liver. Chronic alcohol abuse results in alcohol-induced fatty liver and liver injury. Red quinoa (Chenopodium formosanum) was a traditional staple food for Taiwanese aborigines. Red quinoa bran (RQB) included strong anti-oxidative and anti-inflammatory polyphenolic compounds, but it was usually regarded as the agricultural waste. Therefore, this study is to investigate the effect of water and ethanol extraction products of RQB on the prevention of liquid alcoholic diet-induced acute liver injury in mice. The mice were given whole grain powder of red quinoa (RQ-P), RQB ethanol extract (RQB-E), RQB water extract (RQB-W), and rutin orally for 6 weeks, respectively. The results indicated that RQB-E, RQB-W, and rutin decreased alcoholic diet-induced activities of aspartate aminotransferase and alanine aminotransferase, and the levels of serum triglyceride, total cholesterol, and hepatic triglyceride. Hematoxylin and eosin staining of liver tissues showed that RQB-E and RQB-W reduced lipid droplet accumulation and liver injury. However, ethanol extraction process can gain high rutin and antioxidative agents contents from red quinoa, that showed strong effects in preventing alcoholic fatty liver disease and liver injury via increasing superoxide dismutase/catalase antioxidative system and repressing the expressions of fatty acid synthesis enzyme acetyl-CoA carboxylase.


Subject(s)
Antioxidants/therapeutic use , Chenopodium quinoa , Fatty Liver, Alcoholic/prevention & control , Plant Extracts/therapeutic use , Rutin/therapeutic use , Animals , Antioxidants/chemistry , Chenopodium quinoa/chemistry , Ethanol/adverse effects , Fatty Acids/metabolism , Fatty Liver, Alcoholic/etiology , Fatty Liver, Alcoholic/metabolism , Lipogenesis/drug effects , Male , Mice , Mice, Inbred C57BL , Oxidative Stress/drug effects , Plant Extracts/chemistry , Rutin/chemistry
12.
Nutrients ; 13(5)2021 May 11.
Article in English | MEDLINE | ID: mdl-34064981

ABSTRACT

Alcoholic liver disease (ALD) is one type of liver disease, causing a global healthcare problem and mortality. The liver undergoes tissue damage by chronic alcohol consumption because it is the main site for metabolism of ethanol. Chronic alcohol exposure progresses from alcoholic fatty liver (AFL) to alcoholic steatohepatitis (ASH), which further lead to fibrosis, cirrhosis, and even hepatocellular cancer. Therapeutic interventions to combat ALD are very limited such as use of corticosteroids. However, these therapeutic drugs are not effective for long-term usage. Therefore, additional effective and safe therapies to cope with ALD are urgently needed. Previous studies confirmed that edible food plants and their bioactive compounds exert a protective effect against ALD. In this review article, we summarized the hepatoprotective potential of edible food plants and their bioactive compounds. The underlying mechanism for the prevention of ALD by edible food plants was as follows: anti-oxidation, anti-inflammation, lipid regulation, inhibition of apoptosis, gut microbiota composition modulation, and anti-fibrosis.


Subject(s)
Liver Diseases, Alcoholic/therapy , Plants, Edible/chemistry , Polyphenols/therapeutic use , Protective Agents/therapeutic use , Alcohol Drinking , Animals , Ethanol/adverse effects , Ethanol/metabolism , Fatty Liver, Alcoholic/metabolism , Fatty Liver, Alcoholic/therapy , Gastrointestinal Microbiome/drug effects , Humans , Liver/drug effects , Liver/metabolism , Liver Diseases, Alcoholic/metabolism , Liver Neoplasms , Phytochemicals/chemistry , Phytochemicals/therapeutic use , Plant Extracts/therapeutic use , Protective Agents/chemistry
13.
Biomed Pharmacother ; 134: 111121, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33341668

ABSTRACT

Exessive drinking is commonly associated with a wide spectrum of liver injuries. The term alcoholic liver disease (ALD) is generally used to refer to this spectrum of hepatic abnormalities, and the term hepatic steatosis denotes early lesions. Puerariae Lobatae Radix (PLR) is a common traditional Chinese medicine and has been widely used as an efficient treatment for alcohol-induced damage. Flavonoids are the principal components of PLR that could potentially be responsible for the activation of alcohol metabolism and lipid-lowering effects. However, little is known about the mechanisms underlying their activity against alcoholic injury. In this study, PLR flavonoids (PLF) were obtained by microwave extraction. A 2% ethanol solution was used to establish a model of alcoholic fatty liver disease by exposure of zebrafish larvae for 32 h, and then the zebrafish were administered PLF and puerarin. The results showed that PLF and puerarin significantly decreased lipid accumulation and the levels of total cholesterol and triglycerides in zebrafish larvae. Moreover, PLF and puerarin downregulated the expression of genes related to alcohol and lipid metabolism (CYP2y3, CYP3a65, ADH8a, ADH8b, HMGCRB, and FASN), endoplasmic reticulum stress, and DNA damage (CHOP, EDEM1, GADD45αa, and ATF6) and reduced levels of inflammatory factors (IL-1ß, TNF-α) in zebrafish larvae. PLF and puerarin increased the phosphorylation of AMP-activated protein kinase-α (AMPKα) and decreased the total protein level of ACC1. The findings suggested that PLF and puerarin alleviated alcohol-induced hepatic steatosis in zebrafish larvae by regulating alcohol and lipid metabolism, which was closely related to the regulation of the AMPKα-ACC signaling pathway. In conclusion, the study provided a possible therapeutic drug for ALD treatment.


Subject(s)
Ethanol/metabolism , Fatty Liver, Alcoholic/prevention & control , Flavonoids/pharmacology , Isoflavones/pharmacology , Lipid Metabolism/drug effects , Liver/drug effects , Pueraria , AMP-Activated Protein Kinases/metabolism , Acetyl-CoA Carboxylase/genetics , Acetyl-CoA Carboxylase/metabolism , Animals , Cytokines/genetics , Cytokines/metabolism , Disease Models, Animal , Fatty Liver, Alcoholic/metabolism , Fatty Liver, Alcoholic/pathology , Flavonoids/isolation & purification , Gene Expression Regulation, Enzymologic , Inflammation Mediators/metabolism , Isoflavones/isolation & purification , Liver/metabolism , Liver/pathology , Pueraria/chemistry , Zebrafish/embryology , Zebrafish Proteins/genetics , Zebrafish Proteins/metabolism
14.
Am J Physiol Endocrinol Metab ; 318(5): E655-E666, 2020 05 01.
Article in English | MEDLINE | ID: mdl-32045262

ABSTRACT

Excessive alcohol consumption, including binge drinking, is a common cause of fatty liver disease. Binge drinking rapidly induces hepatic steatosis, an early step in the pathogenesis of chronic liver injury. Despite its prevalence, the process by which excessive alcohol consumption promotes hepatic lipid accumulation remains unclear. Alcohol exerts potent effects on the brain, including hypothalamic neurons crucial for metabolic regulation. However, whether or not the brain plays a role in alcohol-induced hepatic steatosis is unknown. In the brain, alcohol increases extracellular levels of adenosine, a potent neuromodulator, and previous work implicates adenosine signaling as being important for the development of alcoholic fatty liver disease. Acute alcohol exposure also increases both the activity of agouti-related protein (AgRP)-expressing neurons and AgRP immunoreactivity. Here, we show that adenosine receptor A2B signaling in the brain modulates the extent of alcohol-induced fatty liver in mice and that both the AgRP neuropeptide and the sympathetic nervous system are indispensable for hepatic steatosis induced by bingelike alcohol consumption. Together, these results indicate that the brain plays an integral role in alcohol-induced hepatic lipid accumulation and that central adenosine signaling, hypothalamic AgRP, and the sympathetic nervous system are crucial mediators of this process.


Subject(s)
Binge Drinking/metabolism , Fatty Liver, Alcoholic/metabolism , Hypothalamus/metabolism , Lipid Metabolism/physiology , Liver/metabolism , Neurons/metabolism , Agouti-Related Protein/metabolism , Animals , Male , Mice
15.
Nutrients ; 12(1)2020 Jan 19.
Article in English | MEDLINE | ID: mdl-31963802

ABSTRACT

Excess alcohol consumption is a top risk factor for death and disability. Fatty liver will likely develop and the risk of liver disease increases. We have previously demonstrated that an essential amino acid supplement (EAAS) improved protein synthesis and reduced intrahepatic lipid in the elderly. The purpose of this exploratory pilot study was to initiate the evaluation of EAAS on intrahepatic lipid (IHL), body composition, and blood lipids in individuals with mild to moderate alcohol use disorder (AUD). Following consent, determination of eligibility, and medical screening, 25 participants (18 males at 38 ± 15 years/age and 7 females at 34 ± 18 years/age) were enrolled and randomly assigned to one of two dosages: a low dose (LD: 8 g of EAAS twice/day (BID)) or high dose (HD: 13 g of EAAS BID). Five of the twenty-five enrolled participants dropped out of the intervention. Both groups consumed the supplement BID for 4 weeks. Pre- and post-EAAS administration, IHL was determined using magnetic resonance imaging/spectroscopy, body composition was analyzed using dual-energy X-ray absorptiometry, and blood parameters were measured by LabCorp. T-tests were used for statistical analysis and considered significant at p < 0.05. While there was no significant change in IHL in the LD group, there was a significant 23% reduction in IHL in the HD group (p = 0.02). Fat mass, lean tissue mass, bone mineral content, and blood lipids were not altered. Post-EAAS phosphatidylethanol was elevated and remained unchanged in LD at 407 ± 141 ng/mL and HD at 429 ± 196 ng/mL, indicating chronic and excess alcohol consumption. The HD of the proprietary EAAS formulation consumed BID seemed to lower IHL in individuals with mild to moderate AUD. We suggest that further studies in a larger cohort be conducted to more completely address this important area of investigation.


Subject(s)
Alcohol Drinking/adverse effects , Amino Acids, Essential/administration & dosage , Dietary Supplements , Fatty Liver, Alcoholic/drug therapy , Lipids/blood , Liver/drug effects , Adult , Alaska , Amino Acids, Essential/adverse effects , Biomarkers/blood , Body Composition/drug effects , Dietary Supplements/adverse effects , Fatty Liver, Alcoholic/etiology , Fatty Liver, Alcoholic/metabolism , Female , Humans , Liver/metabolism , Male , Middle Aged , Pilot Projects , Time Factors , Treatment Outcome , Young Adult
16.
J Proteome Res ; 18(11): 3821-3830, 2019 11 01.
Article in English | MEDLINE | ID: mdl-31612718

ABSTRACT

Alcoholic steatosis is one of the most prevalent forms of liver disease, and appropriate insight and application of anti-steatosis drugs must be considered. Geniposide, the major active constituent of the Gardenia jasminoides (Ellis) fruit, has been commonly used as a traditional herbal medicine for the treatment of liver diseases. However, its hepatoprotective effect on alcoholic steatosis has not been reported. Moreover, geniposide overdose-induced hepatotoxicity was demonstrated. Hence, its therapeutic effects and overdose-induced hepatotoxicity in rat models along with corresponding targets, especially the targets of transcription factors (TFs), were systematically investigated in this study by using a concatenated tandem array of consensus TF response elements. The results indicate that geniposide can attenuate alcoholic steatosis and liver injury by enhancing the transcriptional activities of peroxisome proliferator-activated receptor-α and hepatocyte nuclear factors 1α and 4α, while geniposide overdose perturbs other TFs. In addition, therapeutic doses and overdoses of geniposide have differentiated target TFs. This study is the first to provide a systematic insight into the difference of critical transcription factors between the actions of therapeutic doses and overdoses of geniposide, as well as much-needed attention to the important topic of alcoholic liver disease therapy.


Subject(s)
Chemical and Drug Induced Liver Injury/metabolism , Fatty Liver, Alcoholic/metabolism , Iridoids/administration & dosage , Proteomics/methods , Transcription Factors/metabolism , Animals , Chemical and Drug Induced Liver Injury/etiology , Drug Overdose/complications , Fatty Liver, Alcoholic/prevention & control , Fruit/chemistry , Gardenia/chemistry , Iridoids/adverse effects , Male , PPAR alpha/metabolism , Phytotherapy/adverse effects , Phytotherapy/methods , Proteome/metabolism , Rats, Sprague-Dawley
17.
An Acad Bras Cienc ; 91(3): e20180646, 2019 Aug 12.
Article in English | MEDLINE | ID: mdl-31411259

ABSTRACT

The hepatoprotective effects of the ethanolic extracts of propolis (EEP) on alcohol-induced liver steatosis were investigated in Wistar rats. Chronic alcoholic fatty liver was induced by administration of 52% alcohol to male Wistar rats at the dose of 1% body weight for 7 weeks. Then animals were simultaneously treated with 50% ethanol solutions of EEP or normal saline at the dose of 0.1% body weight for 4 further weeks. Serological analyses and liver histopathology studies were performed to investigate the development of steatosis. Microarray analysis was conducted to investigate the alterations of hepatic gene expression profiling. Our results showed that 4-week treatment of EEP helped to restore the levels of various blood indices, liver function enzymes and the histopathology of liver tissue to normal levels. Results from the microarray analysis revealed that the hepatic expressions of genes involved in lipogenesis were significantly down-regulated by EEP treatment, while the transcriptional expressions of functional genes participating in fatty acids oxidation were markedly increased. The ability of EEP to reduce the negative effects of alcohol on liver makes propolis a potential natural product for the alternative treatment of alcoholic fatty liver.


Subject(s)
Fatty Liver, Alcoholic/metabolism , Liver Diseases, Alcoholic/metabolism , Plant Extracts/metabolism , Propolis/metabolism , Protective Agents/metabolism , Alanine Transaminase/metabolism , Animals , Apitherapy/methods , Aspartate Aminotransferases/metabolism , Cholesterol/metabolism , Disease Models, Animal , Ethanol , Fatty Acids/biosynthesis , Fatty Liver, Alcoholic/drug therapy , Fatty Liver, Alcoholic/genetics , Fatty Liver, Alcoholic/pathology , Liver Diseases, Alcoholic/drug therapy , Liver Diseases, Alcoholic/genetics , Liver Diseases, Alcoholic/pathology , Male , Oxidation-Reduction , Plant Extracts/chemistry , Plant Extracts/therapeutic use , Propolis/chemistry , Propolis/therapeutic use , Protective Agents/chemistry , Protective Agents/therapeutic use , Rats, Wistar , Tissue Array Analysis/methods , Transcription, Genetic/genetics , Triglycerides/metabolism
18.
Am J Chin Med ; 47(3): 559-575, 2019.
Article in English | MEDLINE | ID: mdl-31012326

ABSTRACT

Alcohol liver disease is a major public health problem associated with lifestyle. Our recent study demonstrated that the roots of Panax notoginseng saponins (PNS) exert hepatoprotective effects against alcohol consumption. Considering that the leaves of Panax notoginseng saponins (LPNS) have similar chemical ingredients with PNS, increased attention should be given to the hepatoprotective effects of LPNS. In this study, a metabonomic approach based on ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UHPLC-QTOF/MS) was developed to evaluate the hepatoprotective effect of LPNS on alcoholic fatty liver and elucidate the interaction mechanisms. Results showed that the ethanol-induced metabolic perturbations were restored after treatment with LPNS. Furthermore, 12 potential biomarkers (11 upregulated and 1 downregulated) were identified by V-plot and orthogonal partial least square discriminant analysis. Changes in the levels of these metabolites indicated that glycerophospholipid and fatty acid metabolism were disturbed in alcoholic fatty liver mouse. Our findings demonstrated that the UHPLC-QTOF/MS-based metabonomic method may provide a useful means for exploring biomarkers involved in alcoholic fatty liver and elucidating the therapeutic effects of LPNS. This work also showed that the metabonomic approach is a powerful and promising tool for the evaluation of the efficacy of traditional Chinese medicine and elucidation of related mechanisms.


Subject(s)
Chromatography, High Pressure Liquid/methods , Drugs, Chinese Herbal/pharmacology , Fatty Liver, Alcoholic/drug therapy , Fatty Liver, Alcoholic/metabolism , Mass Spectrometry/methods , Medicine, Chinese Traditional , Metabolomics/methods , Panax notoginseng/chemistry , Phytotherapy , Plant Leaves/chemistry , Saponins/pharmacology , Animals , Disease Models, Animal , Dose-Response Relationship, Drug , Drugs, Chinese Herbal/therapeutic use , Fatty Liver, Alcoholic/prevention & control , Lipid Metabolism/drug effects , Male , Mice, Inbred C57BL , Saponins/therapeutic use
19.
J Clin Invest ; 129(6): 2305-2317, 2019 03 19.
Article in English | MEDLINE | ID: mdl-30888335

ABSTRACT

Chronic alcohol consumption causes liver injury, inflammation and fibrosis, thereby increasing morbidity and mortality. Paradoxically, modest drinking is believed to confer metabolic improvement, but the underlying mechanism remains elusive. Here, we have identified a novel hepatoprotective brain/brown adipose tissue (BAT)/liver axis. Alcohol consumption or direct alcohol administration into the brain stimulated hypothalamic neural circuits and sympathetic nerves innervating BAT, and dramatically increased BAT uncoupling protein 1 (Ucp1) expression and activity in a BAT sympathetic nerve-dependent manner. BAT and beige fat oxidized fatty acids to fuel Ucp1-mediated thermogenesis, thereby inhibiting lipid trafficking into the liver. BAT also secreted several adipokines, including adiponectin that suppressed hepatocyte injury and death. Genetic deletion of Ucp1 profoundly augmented alcohol-induced liver steatosis, injury, inflammation and fibrosis in male and female mice. Conversely, activation of BAT and beige fat through cold exposure suppressed alcoholic liver disease development. Our results unravel an unrecognized brain alcohol-sensing/sympathetic nerve/BAT/liver axis that counteracts liver steatosis and injury.


Subject(s)
Adipose Tissue, Brown/metabolism , Ethanol/adverse effects , Fatty Liver, Alcoholic/metabolism , Liver/metabolism , Adipose Tissue, Beige/metabolism , Adipose Tissue, Beige/pathology , Adipose Tissue, Brown/pathology , Animals , Cold Temperature , Ethanol/pharmacology , Fatty Liver, Alcoholic/genetics , Fatty Liver, Alcoholic/pathology , Female , Hypothalamus/metabolism , Hypothalamus/pathology , Liver/pathology , Male , Mice , Mice, Knockout , Sympathetic Nervous System/metabolism , Sympathetic Nervous System/pathology , Uncoupling Protein 1/genetics , Uncoupling Protein 1/metabolism
20.
Nutrients ; 10(10)2018 Oct 08.
Article in English | MEDLINE | ID: mdl-30297615

ABSTRACT

A variety of dietary natural products have shown hepatoprotective effects. Increasing evidence has also demonstrated that gut microorganisms play an important role in the hepatoprotection contributed by natural products. Gut dysbiosis could increase permeability of the gut barrier, resulting in translocated bacteria and leaked gut-derived products, which can reach the liver through the portal vein and might lead to increased oxidative stress and inflammation, thereby threatening liver health. Targeting gut microbiota modulation represents a promising strategy for hepatoprotection. Many natural products could protect the liver from various injuries or mitigate hepatic disorders by reverting gut dysbiosis, improving intestinal permeability, altering the primary bile acid, and inhibiting hepatic fatty acid accumulation. The mechanisms underlying their beneficial effects also include reducing oxidative stress, suppressing inflammation, attenuating fibrosis, and decreasing apoptosis. This review discusses the hepatoprotective effects of dietary natural products via modulating the gut microbiota, mainly focusing on the mechanisms of action.


Subject(s)
Biological Products/pharmacology , Diet , Fatty Liver/microbiology , Gastrointestinal Microbiome , Liver Neoplasms/microbiology , Liver , Probiotics , Apoptosis/drug effects , Biological Products/therapeutic use , Dysbiosis/complications , Dysbiosis/drug therapy , Fatty Acids/metabolism , Fatty Liver/metabolism , Fatty Liver/pathology , Fatty Liver/prevention & control , Fatty Liver, Alcoholic/metabolism , Fatty Liver, Alcoholic/microbiology , Fatty Liver, Alcoholic/pathology , Fatty Liver, Alcoholic/prevention & control , Fibrosis/drug therapy , Humans , Inflammation/drug therapy , Intestines/drug effects , Intestines/microbiology , Intestines/pathology , Liver/drug effects , Liver/metabolism , Liver/pathology , Liver Neoplasms/metabolism , Liver Neoplasms/pathology , Liver Neoplasms/prevention & control , Non-alcoholic Fatty Liver Disease/metabolism , Non-alcoholic Fatty Liver Disease/microbiology , Non-alcoholic Fatty Liver Disease/pathology , Non-alcoholic Fatty Liver Disease/prevention & control , Oxidative Stress/drug effects , Plant Extracts/pharmacology , Plant Extracts/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL